A breakthrough alliance

T2EVOLVE works to accelerate development and increase access to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR).

T2EVOLVE explained in 60 seconds

The T2EVOLVE Consortium is made up of 27 European partners from 9 different countries in 8 work packages. See how it works here.

Lymphodepletion: New article emphasises its essential but undervalued part of the CAR T-cell therapy cycle

Latest outcomes from T2EVOLVE

Thank you for joining us in Valencia!

T2EVOLVE wants to thank all participants for joining the annual consortium meeting in Valencia, Spain. The day provided us with a valuable opportunity to connect, share perspectives from the different work packages and engage in meaningful discussions. You can find a...

Lymphodepletion: New article emphasises its essential but undervalued part of the CAR T-cell therapy cycle

T2EVOLVE's latest article tackles one of the most important topics in CAR T-cell therapy: lymphodepletion. While looking into 1271 studies with regard to lymphodepletion stratgies, the authors found that the variability and insufficient amount of detailed information...

Explore T2EVOLVE’s hubs for patients and HCPs

One of the T2EVOLVE consortium's key objectives is to ensure patients have access to the best available care, and being able to provide relevant and reliable information for patients and healthcare professionals is vital in making sure this happens. Because of this,...

Join T2EVOLVE at the 6th European CAR T-cell meeting!

Join us at T2EVOLVE at the 6th European CAR T-cell Meeting in Valencia, Spain on 15-17 February 2024! This event is the biggest of its kind and contains a carefully crafted programme covering a wide range of topics, including deep science, translational research,...

CAR T-cell therapy

Engineered T-cell therapy is a revolutionary cancer treatment where a patient’s immune cells are reprogrammed to seek and destroy cancer cells. This transformative treatment has the potential to cure cancer with a single shot. This therapy is approved and available in the EU for the treatment of leukemia and has the potential to become a blockbuster therapy for other types of cancer, as well as infectious diseases and autoimmune diseases in the future.

For additional information on CAR T-cell technology please contact UKW.


Director CAR-T Research Program, Cellular Immunotherapy for Malignant Diseases Max Eder Research Group‚ CAR T-cell engineering, Universitätsklinikum Würzburg, Germany

Prof Michael Hudecek, MD

T2EVOLVE Project Coordinator

Translational Strategy Leader, Cell Therapies, Takeda Pharmaceuticals, and EFPIA project leader for T2EVOLVE IMI Consortium,
Cambridge, Massachusetts, USA

Dr Rashmi Choudhary, Ph.D.

T2EVOLVE Project Leader


This project received funding from the innovative Medicines initiative 2 Joint Undertaking (JU) under grant agreement No 945393. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programe and EFPIA. More information can be found at: https://www.imi.europa.eu/

Share This